ExpreS2ion Biotech
ExpreS2ion's Associated Company AdaptVac Receives Milestone Payment Following Completion of Bavarian Nordic's Clinical Phase III Study for the COVID-19 Vaccine
REG
CEO Bent Frandsen comments:
"We are pleased to announce that the completion of Bavarian Nordic's clinical Phase III study for the COVID-19 vaccine ABNCoV2 has triggered a milestone payment to AdaptVac, in which ExpreS2ion holds a 34% ownership. The Phase III study served to validate our ExpreS2 technology platform, forming the basis for our ongoing therapeutic HER2+ breast cancer vaccine candidate, ES2B-C001, and future initiatives."
Certified Adviser
Svensk Kapitalmarknadsgranskning AB
| Datum | 2024-02-21, kl 09:00 |
| Källa | Cision |
Vill du synas här? Kontakta hej@allaaktier.se. Vår sajt har 100 000 sidvisningar och 15 000 unika besökare per månad. Vår discord har över 6000 medlemmar. Detta är aktiva sparare med ett stort aktieintresse. Behöver du nå ut till denna målgrupp så hör av dig!